.

Professor Yvonne Perrie

Life & Health Sciences

Professor Yvonne Perrie
  • 1995 - 98
    PhD, The School of Pharmacy, University of London 
    (Supervisor, Prof. G. Gregoriadis) 
  • 1994 - 95
    Pre-registration Pharmacist training, R.W. McConnell & Son, Scotland.
  • 1990 - 94
    BSc Hons, Pharmacy (1st Class), University of Strathclyde

Pharmaceutics and Drug Delivery across a range of programmes including the MPharm programme, OSPAP, MSc in Drug Delivery and MSc in Pharmaceutical Engineering. 

Particulate drug delivery systems (including liposomes, niosomes and nanoparticles) offer a range of advantages for drug delivery, but their clinical application remains under exploited. My research generates a deeper understanding of formulation attributes that govern the mechanism of action of these particulate systems for drug delivery, vaccine adjuvanticity and diagnostics. This reinforces their development and the pathway of these systems into clinical trials and application. By continued systematic development of such systems, my research provides the foundation for practical solutions and realistic options to enhance patient care on a global scale. 

My research group gratefully acknowledges the support of: EPSRC, EU 6th Framework programme, Lipoxen Technologies Ltd, Pfizer Global Research, Astisen Ltd, Wellcome, and The Royal Society.

Papers 

1.Wilkhu JS, McNeil SE, Anderson DE, Perrie Y *(2014). Consideration of the efficacy of non-ionic vesicles in the targeted delivery of vaccines (2014). Drug Delivery and Translational Research, 4 (3), 233-245.

2.Hussain, M. J., Wilkinson, A., Bramwell, V. W., Christensen, D, Perrie, Y* (2014). Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants. J Pharm Pharmacol. 66(3):358-66

3.Wilkhu JS, Ouyang D, Kirchmeier MJ, Anderson DE, Perrie Y* (2014). Investigating the role of cholesterol in the formation of non-ionic surfactant based bilayer vesicles: thermal analysis and molecular dynamics. Int J Pharm. 461 (1-2):331-41.

4.Kaur, R., Henriksen-Lacey, M., Wilkhu, J., Devitt, A., Christensen, D., Perrie, Y *(2014).  The effect of incorporating cholesterol into DDA:TDB liposomal adjuvants on bilayer properties, biodistribution and immune responses. Mol Pharm. 11(1):197-207.

5.Wilkhu JS, McNeil SE, Anderson DE, Perrie Y* (2013). Characterisation and optimisation of bilosomes for oral vaccine delivery. J Drug Target.  21(3): 291–299.

6.Kirby, D. J., Kaur, R., Agger, E. M., Andersen, P., Bramwell, V. W. & Perrie, Y*. (2013). Developing solid particulate vaccine adjuvants - surface bound antigen favours a humoural response, whereas entrapped antigen shows a tendency for cell mediated immunity (2013). Cur Drug Deliv. 10 (3), 268-278.

7.Perrie, Y*., Kastner, E., Kaur, R., Wilkinson, A. & Ingham, A. J (2013).  A case-study investigating the physico-chemical characteristics that dictate the function of a liposomal adjuvant. Hum Vaccin Immunother. 12;9(6).

8.Daneshpour, N., Collighan, R., Perrie, Y., Lambert, P., Rathbone, D., Lowry, D. & Griffin, M.  (2013). Indwelling catheters and medical implants with FXIIIa inhibitors: a novel approach to the treatment of catheter and medical device-related infections, Eur J Pharm Biopharm. 83(1):106-13.

9.Khan, S., Batchelor, H., Hanson, P., Saleem, I. Y., Perrie, Y. & Mohammed, A. R. (2013). Dissolution rate enhancement, in vitro evaluation and investigation of drug release kinetics of chloramphenicol and sulphamethoxazole solid dispersions. Drug Development and Industrial Pharmacy. 39(5):704-15.

10.Kaur, R., Bramwell, V. W., Kirby, D. J. & Perrie, Y* (2012). Manipulation of the surface peglyation in combination with reduced vesicle size of cationic liposomal adjuvants modifies their clearance kinetics from the injection site, and the rate and type of T cell response. J Control Release. 164(3):331-7. 

11.Ali, M. H., Moghaddam, B., Kirby, D. J., Mohammed, A. R. & Perrie, Y*. (2012). The role of lipid geometry in designing liposomes for the solubilisation of poorly water soluble drugs. Int J Pharm 30;453(1):225-32 

12.Christensen, D., Henriksen-Lacey, M., Kamath, A. T., Lindenstrøm, T., Korsholm, K. S., Christensen, J. P., Rochat, A-F., Lambert, P-H., Andersen, P., Siegrist, C-A., Perrie, Y. & Agger, E. M. (2012). Vaccine adjuvants based on saturated quaternary ammonium lipids have different in vivo distribution kinetics and display distinct T cell-inducing capacity compared to their unsaturated analogues. J Control Release, 160 (3) 468-476.

13.Bibi, S., Lattmann, E., Mohammed, A-U-R. & Perrie, Y* (2012). Trigger release liposome systems: local and remote controlled delivery? J Microencapsul. 29(3):262-76.

14.Milicic, A., Kaur, R., Reyes-Sandoval, A., Tang, C-K., Honeycutt, J., Perrie, Y. & Hill, A. V. S. (2012). Small cationic DDA:TDB liposomes as protein vaccine adjuvant obviate the need for TLR agonists in inducing cellular and humoral responses. PLoS ONE. 7(3) e34255.

15.Kaur, R., Bramwell, V. W., Kirby, D. J. & Perrie, Y*. (2012). Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses J Control Release. 158(3) 72-77.

16.Perrie, Y*, Singh Badhan, R., Kirby, D. J., Lowry, D., Mohammed, A-U-R. & Ouyang, D (2012). The impact of ageing on the barriers to drug delivery. J Control Release. 161(2) 389-398.

17.Moghaddam, B., McNeil, S. E., Zheng, Q., Mohammed, A. R. & Perrie, Y*. (2011). Exploring the correlation between lipid packaging in lipoplexes and their transfection efficacy. Pharmaceutics. 3(4), 848-864.

18.Henriksen-Lacey, M., Devitt, A. & Perrie, Y*. (2011). The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production. J Control Release. 154(2):131-7.

19.Al Husban, F., Perrie, Y. &  Mohammed, A-U-R.  (2011). Formulation of multiparticulate systems as lyophilised orally disintegrating tablets. Eur J Pharm Biopharm. 79(3):627-34.

20.S Khan, S., Batchelor, H., Hanson, P., Perrie, Y. & Mohammed, A-U-R (2011). Physicochemical characterisation, drug polymer dissolution and in vitro evaluation of phenacetin and phenylbutazone solid dispersions with polyethylene glycol 8000. J Pharm Sci 100(10), 4281-4294.

21.Moghaddam, B., McNeil, S. E., Zheng, Q., Mohammed, A. R. & Perrie, Y * (2011). The application of monolayer studies in the understanding of liposomal formulations. Int J Pharm. 417 (1-2) 235-244. 

22.Jones, R. J., Rajabi-Siahboomi, A., Levina, M., Perrie, Y. & Mohammed, A. R. (2011). The influence of formulation and manufacturing process parameters on the characteristics of lyophilised orally disintegrating tablets. Pharmaceutics. 3, 440-457.

23.Wilkhu J, McNeil SE, Kirby DJ, Perrie Y*. (2011). Formulation design considerations for oral vaccines. Therapeutic Delivery. 2(9) 1141-1164

24.Carstens, M. G., Camps, M. G. M., Henriksen-Lacey, M., Franken, K., Ottenhoff, T. H. M., Perrie, Y., Bouwstra, J. A., Ossendorp, F. & Jiskoot, W. (2011). Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines. Vaccine 29(29-30):4761-70.

25.Henriksen-Lacey, M., Korsholm, K. S., Andersen, P., Perrie, Y. & Christensen, D.  (2011). Liposomal Vaccine Delivery systems. Expert opin Drug Deliv. 8(4):505-519.

26.Kaur, R., Chen, J., Dawoodji, A., Cerundolo, V., Garcia-Diaz, Y. R., Wojno, J., Cox, L. R., Besra, G. S., Moghaddam, B. & Perrie, Y*. (2011). Preparation, characterisation and entrapment of a non-glycosidic threitol ceramide into liposomes for presentation to invariant natural killer T cells. J Pharm Sci. 100(7):2724-33.

27.McNeil, S. E., Griffiths, H. R. & Perrie, Y*. (2011). Polycaprolactone fibres as a potential delivery system for collagen to support bone regeneration. Curr Drug Deliv. 8(4)448-455.

28.S Khan, S., Elshaer, A., Rahman, A. S., Hanson, P., Perrie, Y. & Mohammed, A-U-R (2011). Systemic biology approach to study permeability of paracetamol and its solid dispersion. Int J Pharm. 417 (1-2) 272-279.

29.Bibi, S., Kaur, R., Henriksen-Lacey, M., McNeil, S. E., Wilkhu, J., Lattmann, E., Christensen, D., Mohammed, A-U-R. & Perrie, Y*. (2011). Microscope imaging of liposomes: From coverslips to environmental SEM. Int J Pharm. 417 (1-2) 138-150.

30.Anjumn Shabir, Farhan AlHusban, Yvonne Perrie and Afzal R Mohammed (2011). Effects of ball-milling on PLGA polymer and its implication on lansoprazole-loaded nanoparticles. Journal of Basic and Clinical Pharmacy 2,71-82

31.McNeil, S. E., Rosenkrands, I., Agger, E. M., Andersen, P., Perrie, Y. & Agger, E. M. (2011). Subunit vaccines: Distearoylphosphatidylcholine based liposomes entrapping antigen offer a neutral alternative to dimethyldioctadecylammonium based cationic liposomes as an adjuvant delivery system. J Pharm Sci. 100(5)1856-65.

32.Henriksen-Lacey, M., Christensen, D., Bramwell, V. W., Lindenstrøm, T., Agger, E. M., Andersen, P. & Perrie, Y*. (2011). Comparison of the depot effect and immunogenicity of liposomes based on DDA, DC-Chol and DOTAP: Prolonged liposome retention mediates stronger Th1 responses. Molecular Pharmaceutics. Mol Pharm. 8(1):153-61.

33.Khan S, Elshaer A, Rahman AS, Hanson P, Perrie Y, Mohammed AR (2011). Genomic evaluation during permeability of indomethacin and its solid dispersion. J Drug Target. 19 (8) 615-623.

34.Daneshpour, N., Griffin, M., Collighan, R. & Perrie, Y*. (2011) Targeted delivery of a novel group of site directed transglutaminase inhibitors to the liver using liposomes: a new approach for the potential treatment of liver fibrosis. J Drug Target. 19 (8) 624-631.

35.Ali, M.H., Kirby, DJ, Mohammed AR, Perrie Y* (2010). Solubilisation of drugs within liposomal bilayers – alternatives to cholesterol as a membrane stabilising agent. J Pharm Pharmacol. 62 (11): 1646-1655.

36.R Mohammed, A-U-R., Bramwell, V. W., Kirby, D. J., McNeil, S. E. & Perrie, Y*. (2010). Increased Potential of a Cationic Liposome Based Delivery System: Enhancing Stability and Sustained Immunological Activity in Pre-Clinical Development. Eur J Pharm Biopharm. 76(3):404-12.

37.Mohanan, D., Slütter, B., Henriksen-Lacey, M., Jiskoot, W., Bouwstra, J. A., Perrie, Y., Kündig, T. M., Gander, B. & Johansen, P. (2010). Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems. J Control Release. 147(3), 342-249.

38.Henriksen-Lacey, M., Christensen, D., Bramwell, V. W., Lindenstrøm, T., Agger, E. M., Andersen, P. & Perrie, Y*. (2010). Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and immunogenicity of the vaccine. J Control Release. 145; 102-108.

39.Henriksen-Lacey, M., Bramwell, V. & Perrie, Y*. (2010). Radiolabelling of Antigen and Liposomes for Vaccine Biodistribution Studies. Pharmaceutics, 2, 91-104; doi:10.3390/pharmaceutics2020091.

40.Al Husban, F., Perrie, Y. & Mohammed, A. R.  (2010). Formulation and characterisation of lyophilised rapid disintegrating tablets using amino acids as matrix forming agents.  Eur J Pharm Biopharm. 75(2), 254-262.

41.McNeil SE, Vangala, A, Bramwell, VW, Hanson, PJ and Perrie, Y* (2010). Lipoplexes formulation and optimisation: In vitro transfection studies reveal no correlation with in vivo vaccination studies. Current Drug Delivery. 7, 175-187.

42.Chang, H-I., Wang, Y., Perrie, Y. and Coombes, A.G.A (2010). Microporous polycaprolactone matrices for drug delivery and tissue engineering: the release behavior of bioactive having extremes of aqueous solubility.  J Drug Del Sci Tech., 20(3) 207-212.

43.Smith AM, Ingham A, Grover LM and Perrie Y* (2010). Polymer film formulations for the preparation of enteric pharmaceutical capsules. J Pharm Pharmacol. 62 (2): 167-172.

44.Henriksen-Lacey, M., Bramwell, V. W., Christensen, D., Agger, E. M., Andersen, P. & Perrie, Y*. (2010). Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. J Control Release. 142 (2) 180-186.

45.Perrie Y*, Ali H, Kirby DJ, Mohammed AU, McNeil SE, Vangala A (2010). Environmental scanning electron microscope imaging of vesicles. Methods Mol Biol; 606:319-331.

46.AlHusban, F., Elshaer, A. M., Kansara, J. H., Smith, A. M., Grover, L. M., Perrie, Y. & Mohammed, A-U-R. (2010). Investigation of Formulation and Process of Lyophilised Orally Disintegrating Tablet (ODT) Using Novel Amino Acid Combination. Pharmaceutics. 2(1), 1-17. http://www.mdpi.com/1999-4923/2/1/1/pdf

47.Alhusban F, Perrie Y, Mohammed AR (2010). Preparation, Optimisation and Characterisation of Lyophilised Rapid Disintegrating Tablets Based on Gelatin and Saccharide. Curr Drug Deliv. 7, 65-75.

48.Kaur, R., Morris, R., Bencsik, M., Vangala, A., Rades, T. & Perrie, Y*. (2009) Development of a novel magnetic resonance imaging contrast agent for pressure measurements using lipid-coated microbubbles. J Biomed Nanotechnol. 5 (6), 1-9.

49.Christensen D, Agger EM, Andreasen LV, Kirby, DJ, Andersen P, Perrie Y* (2009). Liposome-based cationic adjuvant formulations (CAF): Past, present, and future. J Liposome Res. 19(1) 2-11.

50.Bhowruth V, Minnikin DE, Agger EM, Andersen P, Bramwell VW, Perrie Y*, Besra GS (2009) Adjuvant properties of a simplified C32 monomycolyl glycerol analogue. Bioorg Med Chem Lett. 2009 19(7) 2029-32.

51.Hofmann, MP, Mohammed AR, Perrie Y, Gbureck U, Barralet JE* (2009) High Strength brushite bone cement with controlled drug releasing capabilities. Acta Biomater 5(1):43-49.  

52.Perrie, Y*, Mohammed, A.R., Kirby, D.J., McNeil, S.E. and Bramwell, V.W. (2008) Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int. J Pharm. 364,272-280.

53.Clark, S., Cross, L M., Smith, A.M., Court, P., Vipond J, Nadian, A., Hewinson R.G., Batchelor H, K.,   Perrie, Y., Williams, A., Aldwell, F.E. &. Chambers, M.A. (2008) Assessment of different formulations of oral Mycobacterium bovis Bacille Calmette-Guerin (BCG) vaccine in rodent models for immunogenicity and protection against aerosol challenge with M Bovis. Vaccine. 26(46): 5791-7.

54.Perrie, Y*. (2008). Gregory Gregoriadis: Introducing liposomes to drug delivery. J Drug Target. 16(7):518-9.

55.Kirby, DJ, Rosenkrands, I., Agger, E-M. Andersen, P., Coombes AGA., and Perrie, Y* (2008). Liposomes act as stronger sub-unit vaccine adjuvants when compared to microspheres. J. Drug Target, 16(7):543-54.

56.Morris, R. H., Bencsik, M., Nestle, N., Galvosas, P., Fairhurst, D., Vangala, A., Perrie, Y. & McHale, G. (2008). Robust spatially resolved pressure measurements using MRI with novel buoyant-advection free preparations of stable microbubbles in polysaccharide gels. J Magn Reson; 193(2):159-67.

57.Christensen D, Kirby D, Foget C, Agger EM, Andersen P, Perrie Y, Nielsen HM (2008). alpha,alpha'-trehalose 6,6'-dibehenate in non-phospholipid-based liposomes enables direct interaction with trehalose, offering stability during freeze-drying.Biochim Biophys Acta. 2008; 1778(5):1365-1373. 

58.Kirby, DJ, Rosenkrands, I., Agger, E-M. Andersen, P., Coombes AGA., and Perrie, Y* (2008). PLGA microspheres for the delivery of a novel subunit TB vaccine J. Drug Target, 2008; 16(4) 282-293.

59.Vangala, AK, R.H.Morris, RH, Bencsik, M, and Perrie, Y* (2007). Preparation and characterization of gas-filled liposomes: Can they improve oil recovery. J Liposome Res., 17(3):263-272.

60.Smith, AM., Shelton, RM Perrie, Y and Harris, JJ* (2007). An initial evaluation of gellan gum as a material for tissue engineering applications. J Biomater Appl, 2007. 22(3); 241-254. doi:10.1177/0885328207076522

61.Perrie, Y*., Mohammed, A.R., Vangala, A., and McNeil, S.E (2007). Environmental Scanning Electron Microscopy Studies of Liposomes and Niosomes, J Liposome Res. 17(1): 27-37.

62.Perrie, Y*., Kirby, DJ., Bramwell, V.W. and Mohammed, A.R (2007). Recent developments in particulate vaccines. Recent Patents on Drug Delivery & Formulation. 1, 117-129.

63.Morris, R. H., Bencsik, M., Vangala, A. K. & Perrie, Y*. (2007) Three dimensional fluid pressure mapping in porous media using magnetic resonance imaging with gas filled liposomes. Mag. Res. Imaging, 25(4) 509-512. 

64.Smith, AM., Harris, JJ, Shelton, RM and Perrie, Y*. (2007) 3D culture of bone-derived cells immobilized in alginate following light-triggered gelation. J. Control. Release.  94-101. 

65.Vangala, A., Bramwell, V.W., McNeil, E, Christensen, D., Agger, E-M., and Perrie, Y*. (2007) Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen. J. Control. Release. 119(1):102-110. 

66.Mohammed, AR., Coombes, AGA., and *Perrie, Y (2007) Amino Acids as Cryoprotectants for Liposomal delivery systems. Euro J Pharm Sci, 406-413. 

67.Mohammed, A.R., Bramwell, V.W., Coombes, A.G.A., *Perrie, Y (2006). Lyophilisation and sterilisation of liposomal vaccines to produce stable and sterile products. Methods, 40: 30-38. 

68.Vangala. A.K., Kirby, D., Rosenkrands, I., Agger, E-M., Andersen, P. and. *Perrie, Y (2006) A comparative study of cationic liposomes and niosome-based adjuvant systems for protein subunit vaccines: Characterisation, Environmental Scanning Electron Microscopy analysis and immunisation studies. J. Pharm Pharmacol, 58:787-799.

69.Bramwell V.W. & Perrie, Y* (2006). Particulate delivery systems for vaccines: What can we expect? J. Pharm Pharmacol, 58:717-28.

70.McNeil, S.E. and *Perrie, Y (2006). Gene Delivery using cationic lipids. Expert Opinion in Therapeutic Patents. 16(10):1371-1382.

71.Chang, H-I., Perrie, Y. and *Coombes, A.G.A (2006). Delivery of the antibiotic gentamicin sulphate from precipitation cast matrices of polycaprolactone.  J. Control. Release, 110:414-421

72.Gorst, N.J.S.,  Perrie, Y., Gbureck, U.,  Hutton, A.L., Hofmann, M.P., Grover L.M.,  and Barralet J.E (2006). Effect of fibre reinforcement on the mechanical properties of brushite cement.  Acta Biomater, 2(1):95-102.

73.Davidsen, J., Rosenkrands, I., Christensen, D., Vangala, A., Kirby, D., Perrie, Y., Agger, E-M., *Andersen, P (2005). Characterization of cationic liposomes based on dimethyl dioctadecyl ammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6‘-dibehenate) - a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta, 1718, 22-31.

74.Bramwell, V.W. & *Perrie, Y (2005) The rational design of vaccines. Drug Discov Today, 10 (22) 1527-1534.

75.Chang, H-I., Williamson, M.R., Perrie, Y. and *Coombes, A.G.A. Precipitation casting of Drug-loaded microporous PCL Matrices: Incorporation of Progesterone by co-dissolution.  J. Control. Release, 2005, 106,(3): 263-272. 

76.Bramwell, V.W. & *Perrie, Y (2005). Particulate delivery systems for vaccines. Crit Rev Ther Drug Carrier Syst, 2005, 22(2):151-214.

77.Mohammed, A.R., Coombes, A.G.A, Fitzgerald, M., and *Perrie, Y (2004) Liposome formulation of poorly water soluble drugs: Optimisation of drug loading and ESEM analysis of stability. Int. J. Pharm, 285, 23-34.

78.*Perrie, Y., Barralet, J.E., McNeil, S. and Vangala. A.K (2004) Liposome and niosome mediated DNA vaccination via the subcutaneous route. Int. J. Pharm, 284, 31-41.

79.*Perrie, Y., McNeil, S. and Vangala. A.K (2003). Liposome-mediated DNA immunisation via the subcutaneous route. J. Drug Targeting, 11, 555-563.

80.Perrie, Y. Obrenovic, M, McCarthy, D. and Gregoriadis, G (2002). Liposome-mediated DNA vaccination via the oral route. J Liposome Res, 12,185-197

81.Perrie, Y., Frederik P.M., and Gregoriadis, G (2001). Liposome-mediated DNA immunisation: The effect of vesicle composition. Vaccine, 19, 3301-3310 

82.Perrie, Y. and Gregoriadis, G (2000). Liposome-entrapped plasmid DNA: Characterisation Studies.  Biochim Biophys Acta, 1475,125-132.

83.Gregoriadis, G., McCormack, B., Obrenovic, M., and Perrie, Y. (2000) Entrapment of Plasmid DNA Vaccines into Liposomes by Dehydration/Rehydration. Methods Mol Med; 29:305-311.

84.Gregoriadis, G., McCormack, B., Obrenovic, M., Saffie, R., Zadi, B. and Perrie, Y (1999). Vaccine entrapment in Liposomes. Methods, 19,156-162.

Editorials

85.Wilson, K. A. & Perrie, Y. (2013) Introducing Pharmacy - a journal of pharmacy education and practice.  Pharmacy. 1, 1, 1-2.

86.Rades T and Perrie Y (2011). Advanced characterisation techniques. International Journal of Pharmaceutics. 417 (1-2): 1-2.

87.Perrie Y and Rades T (2010). Themed Issue. Improve dissolution, solubility and bioavailability of poorly soluble drugs. J Pharm Pharmacol. 62(11):1517-8 

88.Perrie, Y. & Mohammed, A-U-R (2009).Pharmaceutics: a new open-access journal for all those interested in designing medicines  In : Pharmaceutics. 1, 1. 1-2.

89.Perrie Y. (2009). Liposomes, lipid assemblies, nanotechnology, and everything interesting in between. J liposome Res (Editorial). 19(1):1

90.Perrie Y and Mohammed AR (2009). Pharmaceutics: A New Open-access journal for all those interested in designing medicines. 1(1), 1-2. 

Journals (Professional - other)

91.McNeil S.E and Perrie Y (2010).  Developing a safe lypohilised adjuvant vaccine. Pharmaceutical Technology Europe. March 2010, p14.

92.Perrie, Y*, Smith, AM., Harris, JJ, and Shelton, RM (2006). A new trick for an old delivery system. Pharm J.  277: 780.

93.Perrie, Y. Influenza symptoms and treatments. Pharm J. 2006, 277: 399:402.

94.Perrie, Y. Vaccines: an overview and update. Pharm J. 2006. 276(7388): 209-212.

95.Perrie, Y (2005) How Pharmaceutical Scientists are going prospecting for black gold. Pharm J.  275(1): 809. 

Published articles (Education)

96.Perrie, Y. Optimisation of assessment and feedback in large-group practicals. J Pharm Pharmacol. 2004, 56.

97.Perrie, Y. Turning a dull lecture into an unforgettable learning experience. Pharm. J. 2003a, 270, 754-6.

98.Perrie, Y. Virtual Learning Environments. Pharm. J. 2003b, 270, 794-5.

99.Perrie, Y. Choosing an Assessment Strategy. Pharm. J. 2003c, 271, 86-88. 

100.Wittingham, C and Perrie, Y. (2002). Application of “Exocharmic” Demonstrations in Pharmaceutics Lectures. Pharmacy Education, 2002, 2,157-8.

Patents

101.Anderson D, Kirchmeier, M, Campbell, M, Wilkhu J, Perrie Y. Methods for preparing vesicles and formulations produced thereform. International PCT Patent Application No: PCT/US12/21389. 2012. WO Patent 2,012,097,347

102.Mohammed AUR, Alhusban F, Perrie Y. Orally disintegrating tablets. 16 Nov 2009 GB 0920041.1.

103.Mohammed, A-U-R. & Perrie, Y. A freeze-dried tablet. 9 Apr 2010 GB 1005976.4

104.Smith, AM. & Perrie Y. Enteric Pharmaceutical Capsules. Filed 26/03/08 GB/29.3.07/GBA  0706178. PCT/GB2008001038

105.Perrie, Y. Griffiths, H.R., Phillips, D.C. Ceramide derivatives for the treatment of inflammation. 2004. Patent number W02004064823. (Published 05/08/2004)

106.Gregoriadis, G. and Perrie, Y. Liposome-entrapped DNA oral vaccines. 2001 Patent number WO0124773, (Published 12/04/2001)

Reviews (Invited)

107.Bramwell, V.W. & Perrie, Y (2007). Natural and synthetic additives. European Biopharmaceutical Review. Spring: 78-83.

108.Perrie, Y (2005) Liposome delivery of sparingly soluble drugs.  European Biopharmaceutical Review. Autumn: 90-97.

109.Mohammed, A.R. & *Perrie, Y. (2005) Liposome solutions for sparingly soluble drugs. Drug Delivery Companies Report. Autumn/Winter, 2005, 9-11.

Book Chapters

110.Perrie, Y., Kaur, R., Henriksen-Lacey, M. Fundamentals of Pharmaceutical Nanoscience. The use of Nanotechnology in the formulation of vaccines. Submitted.

111.Perrie Y (2012). Pharmaceutical nanotechnology and nanomedicines. In Aulton’s Pharmaceutics: The design and manufacture of medicines, 4th Edition, Churchill Livingston. 

112.Kirby DJ, Kaur R, and Perrie Y (2012). Formulation and characterisation of PLGA microspheres as vaccine adjuvants. In Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines. D Flower and Y Perrie eds. Springer Science, New York.

113.Wilkhu J, Vangala A, Mohammed AUR, and Perrie Y (2012). Enhancing the delivery and potency of antigens using non-ionic based vesicles. In Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines. D Flower and Y Perrie eds. Springer Science, New York.

114.Henriksen-Lacy, M, and Perrie Y (2012). Designing liposomes as vaccine adjuvants. In Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines. D Flower and Y Perrie eds. Springer Science, New York.

115.Bowman BJ, Ofner CM, Schott, H and Perrie Y (2012). Colloidal Dispersions. In Remington, The Science and Practice of Pharmacy. 22nd Edition. Lippincott Williams & Wilkins.

116.Perrie Y (2010). Vaccines for a new era. In The new optimists: scientists view tomorrow’s world & what it means to us. Linus Publishing. 

117.Gregoriadis G, and Perrie Y. (2010). Liposomes. In Encyclopaedia of Life Sciences. John Wiley & Sons, UK. DOI: 10.1002/9780470015902.a0002656.pub2

118.Yvonne Perrie*, Habib Ali, Daniel J Kirby, Afzal U. R. Mohammed, Sarah E. McNeil, and Anil Vangala (2010). Environmental Scanning Electron Microscope imaging of vesicle systems. In LIPOSOMES, Methods in Molecular Biology. Humana Press (USA) under John M. Walker as the Series Editor OM

119.Christensen D, Korsholm K, Wood KJ, Mohammed AM, Bramwell VW, Agger EM and Perrie Y (2009). Liposomes as adjuvant systems for parenteral delivery of vaccines. In Delivery Technologies for Biopharmaceuticals: Peptides, Proteins, Nucleic Acids and Vaccines. 

120.Gregoriadis, G., McCormack, B., Perrie, Y., Bacon, A., Caparros-Wanderley, W. and Zadi, B.(2003). Liposome-based DNA vaccines: Procedures for entrapment. In Liposomes - A practical approach, 2nd ed., V.P. Torchilin, and V. Weissig eds. Oxford University Press. Practical Approach Series. 

121.Perrie, Y. and Gregoriadis, G. (2000) Liposomal DNA Vaccines: Structural Characteristics. In Gregoriadis and McCormack, (Ed.) Targeting of Drugs, Targeting of Drugs: Strategies for Gene Constructs and Delivery. p. 102-111, Amsterdam, The Netherlands: IOS Press.

122.Gregoriadis, G., McCormack, B., Obrenovic, M., Perrie, Y. and Yang, J-C. (2000) Genetic Vaccines: A Role for Liposomes. In Gregoriadis and McCormack, (Ed.) Targeting of Drugs, Targeting of Drugs: Strategies for Gene Constructs and Delivery, p. 92-110. Amsterdam, The Netherlands: IOS Press.

123.Gregoriadis, G., McCormack, B., Obrenovic, M., Perrie, Y. and Saffie, R. (2000) 

Liposomes As Immunological Adjuvants and Vaccine Carriers. In O'Hagen D.T. (Ed). Methods in Molecular Medicine, vol 42, Vaccine Adjuvants: Preparation Methods and Research Protocols. p. 137-150. Totowa, NJ: Humana Press Inc

124.Gregoriadis, G., McCormack, B., Morrison (Perrie), Y., Saffie, R. and Zadi, B. (1998) Liposomes in drug targeting. In: Cullis, J.E. (Ed.) Cell biology: A laboratory handbook, 2nd edn. p. 131-140. New York: Academic Press.

125.Gregoriadis, G., McCormack, B., Perrie, Y. and Saffie, R. (1998) DNA Vaccination: A role for liposomes. In: Lasic, D.D. and Papahadjopoulos, D. (Eds.) Medical applications of liposomes, p. 61-73. New York: Elsevier Science

126.Gregoriadis, G., McCormack, B., Perrie, Y. and Saffie, R. (1998) Liposome-mediated DNA vaccination. In: Janoff, A. (Ed.) Liposomes: Rational Design, p. 205-218. New York: Marcel Dekker, Inc

Books - written

  •  FASTtrack Pharmaceutics – Drug Delivery and Targeting (2012). Yvonne Perrie and Thomas Rades. London: Pharmaceutical Press. Second Edition.
  •  FASTtrack Pharmaceutics – Drug Delivery and Targeting (2009). Yvonne Perrie and Thomas Rades. London: Pharmaceutical Press.

Books – edited.

  • Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines (2012). Darren Flower and Yvonne Perrie. Springer.
  • Remington: The Science and Practice of Pharmacy (2012). 22

Position: Professor in Pharmaceutics/Drug Delivery, Head of Pharmacy
Phone: 0121 204 3991
Emaily.perrie@aston.ac.uk 
Room: MB325A

Yvonne Perrie's research team
Our research team

Employable Graduates; Exploitable Research